- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02867319
Safety Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old
15. august 2016 opdateret af: Beijing Chaoyang District Centre for Disease Control and Prevention
This phase I clinical study evaluates the safety of ACYW135 meningococcal polysaccharide vaccine in population aged 2-6, 7-17, 18-50 years old by the method of both passive and active surveillance.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
60
Fase
- Fase 1
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
2 år til 50 år (Barn, Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- With the subject (or his guardian's) informed consent and signed the informed consent;
- The history, physical examination and clinical judgement were determined to be healthy and in accordance with the vaccination age of the product;
- The Subject or his guardian could comply with the clinical study protocol;
- Have not been inoculated with Meningococcal vaccine in the past six months and A + C meningococcal polysaccharide vaccine in the past two years;
- Have not been inoculated with other preventive biological products;
- Axillary temperature≤37.0 ℃.
Exclusion Criteria:
- Children with the history of Neisseria meningitis;
- Had allergies or serious adverse reactions of previous vaccination, such as allergies, urticaria, dyspnea, edema, abdominal pain, etc;
- Had immune inhibitor therapy and cytotoxic therapy, inhaled corticosteroids in the past 6 months (not including allergic rhinitis corticosteroid aerosol therapy, patients with acute non concurrent dermatitis surface corticosteroid therapy);
- Have been accepted blood products in the past 3 months;
- Have been inoculated with other research drugs or vaccines in the past month;
- Have been inoculated with attenuated live vaccine in the past 14 days;
- Have been inoculated with subunit or inactivated vaccine in the past 7 days;
- Had any acute illness, the need for systemic application of antibiotics or antiviral treatment in the past 7 days;
- Had fever in the past 3 days (axillary temperature≥38.0℃) ;
- Have been diagnosed with abnormal coagulation function (such as the lack of coagulation factors, coagulation disorders and abnormal blood platelet), obvious bruises or coagulation disorders by physician diagnosis;
- Had the history of thyroid resection or the need for treatment of thyroid diseases in the past 12 months;
- Asplenia, functional asplenia and asplenia or splenectomy of any situation;
- Had epilepsy, convulsions, encephalopathy, mental illness or family history;
- Suffering from serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia, neurological disorders or Guillain-Barre syndrome);
- Suffering from known or suspected concurrent diseases including: respiratory diseases, acute or chronic infection of the activities, children's mother or the subject had HIV infection, cardiovascular disease, high blood pressure, during cancer treatment period, skin diseases;
- The female during her pregnant and lactation period or who plan to become pregnant during the trial.
- The subject of any other factors that are not suitable to participate in clinical trials according to the researcher's judgment.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: age of 18-50 years old
|
A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
|
|
Eksperimentel: age of 7-17 years old
|
A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
|
|
Eksperimentel: age of 2-6 years old
|
A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The rate of adverse reactions of ACYW135 meningococcal polysaccharide vaccine
Tidsramme: 28 days
|
Adverse reactions associated with vaccine will be observed in subjects after each vaccination.
Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site.
solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy
|
28 days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. marts 2016
Primær færdiggørelse (Faktiske)
1. juli 2016
Datoer for studieregistrering
Først indsendt
11. august 2016
Først indsendt, der opfyldte QC-kriterier
11. august 2016
Først opslået (Skøn)
15. august 2016
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
16. august 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
15. august 2016
Sidst verificeret
1. august 2016
Mere information
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Meningokok
-
University GhentUniversity Hospital, Ghent; Centre for Vaccinology - CEVACRekrutteringTranskønnede personer | Vaccination | Kønsforskelle i immunrespons | Meningokok Meningitis, Serogruppe BBelgien
Kliniske forsøg med A dose of ACYW135 meningococcal polysaccharide vaccine
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdAktiv, ikke rekrutterende
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdAktiv, ikke rekrutterende
-
Sanofi Pasteur, a Sanofi CompanyAfsluttetMeningokokvaccination (raske frivillige)Danmark, Finland, Tyskland
-
SanofiAfsluttet
-
CanSino Biologics Inc.Aktiv, ikke rekrutterende
-
GlaxoSmithKlineAfsluttet
-
Sanofi Pasteur, a Sanofi CompanyAfsluttetSunde frivillige | MeningokokvaccinationSydafrika, Indien
-
GlaxoSmithKlineBill and Melinda Gates Foundation; Wellcome Trust; Biomedical Advanced Research... og andre samarbejdspartnereAfsluttetSalmonella infektionerBelgien, Malawi